Literature DB >> 14400598

Studies on fluorinated pyrimidines. X. In vivo studies on tumor resistance.

C HEIDELBERGER, A GHOBAR, R K BAKER, K L MUKHERJEE.   

Abstract

Entities:  

Keywords:  NEOPLASMS/experimental; PYRIMIDINES/metabolism

Mesh：

Substances：

Year:  1960        PMID： 14400598

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  7 in total

1.  Fragment-based discovery of novel thymidylate synthase leads by NMR screening and group epitope mapping.

Authors:  Darren W Begley; Suxin Zheng; Gabriele Varani
Journal:  Chem Biol Drug Des       Date:  2010-07-05       Impact factor: 2.817

Review 2.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

3.  [Studies on combined cytostatic therapy. The effect of cyclophosphamide and mitomycin C on the cortisone degradation of the liver].

Authors:  L Lutzmann; C G Schmidt
Journal:  Klin Wochenschr       Date:  1965-11-15

4.  5-Fluorouracil resistance in carrot cell cultures : Its use in studying the interaction of the pyrimidine and arginine pathways.

Authors:  Z R Sung; S Jacques
Journal:  Planta       Date:  1980-04       Impact factor: 4.116

5.  Uridine kinase activities and pyrimidine nucleoside phosphorylation in fluoropyrimidine-sensitive and -resistant cell lines of the Novikoff hepatoma.

Authors:  N Greenberg; D E Schumm; T E Webb
Journal:  Biochem J       Date:  1977-05-15       Impact factor: 3.857

6.  5-Fluorouracil's cytotoxicity is enhanced both in vitro and in vivo by concomitant treatment with hyperthermia and dipyridamole.

Authors:  Y Maehara; Y Sakaguchi; I Takahashi; M Yoshida; H Kusumoto; H Masuda; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 7.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.